Analyst firms · Jefferies · GMAB

Jefferies GMAB price target and rating history

Genmab A/S (GMAB) · Health Care

Jefferies rates Genmab A/S (GMAB) Buy with a $41.50 price target, as of its latest action on Feb 17, 2026. It has published 3 rating actions on GMAB since September 2021, including 0 upgrades and 2 downgrades. Across 6 firms with a GMAB price target in the last 12 months, the median target is $40. Jefferies's $41.50 is 4% above that.

Current rating

Buy

Price target

$41.50

Median target, all firms

$40

Actions on GMAB

3

Jefferies price target on GMAB

Every Jefferies rating on GMAB

• Feb 17, 2026
  ResumeJefferies resumes coverage at Buy, price target $41.50
• Sep 16, 2021
  DowngradeJefferies downgrades to Hold from Buy
• Sep 16, 2021
  DowngradeJefferies downgrades to Hold from Buy, price target $45.50 to $48

How other firms rate GMAB

Each firm's latest rating and stated target in the last 12 months.

Questions about Jefferies and GMAB

What is Jefferies's price target for GMAB?

Jefferies's latest stated price target for Genmab A/S (GMAB) is $41.50, from its action on Feb 17, 2026.

What is Jefferies's rating on GMAB?

Jefferies rates GMAB Buy, a bullish rating, as of Feb 17, 2026.

When did Jefferies last change its view on GMAB?

On Feb 17, 2026, Jefferies resumes coverage at Buy, price target $41.50.

How does Jefferies's GMAB target compare with other analysts?

Across 6 firms with a GMAB price target in the last 12 months, the median target is $40. Jefferies's $41.50 is 4% above that.

More GMAB rating histories

• Morgan Stanley4
• Leerink Partners3
• UBS3
• H.C. Wainwright3

All Jefferies ratingsGMAB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.